Lasofoxifene Tartrate CAS 190791-29-8 Puritas Chiral ≥99.0% Puritas ≥98.0% (HPLC) API High Purity Featured Image

Lasofoxifene Tartrate CAS 190791-29-8 Puritas chiralis ≥99.0% Puritas ≥98.0% (HPLC) API Alta Puritas

Description:

Chemical Name: Lasofoxifene Tartrate

CAS: 190791-29-8

Aspectus: Alba ad Off-White pulveris

Puritas Chiral: ≥99.0%Puritas: ≥98.0% (HPLC)

In curatione Osteoporosis Postmenopausalis

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple cum High puritate et stabulo Quality
Chemical Name: Lasofoxifene Tartrate
CAS: 190791-29-8
Lasofoxifene Tartrate (CAS: 190791-29-8) in curatione Osteoporosis Postmenopausalis

Chemical Properties:

Nomen chemicum	Lasofoxifene Tartrate
Synonyma	(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol Tartrate Oporia
CAS Number	190791-29-8
CATTUS Number	RF-API20
Stock Status	In Stock, Productio Ascendite usque ad Centum chiliogrammata
Formulae hypotheticae	C28H31NO2.ClH
M. Pondus	450.019
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White pulveris
Humor (KF)	≤0.50%
Metalla gravis	≤20ppm
Chiral Puritas	≥99.0%
Puritas / Analysis Methodus	≥98.0% (HPLC)
Damnum in Siccatio	≤0.50%
Residere in Ignition	≤0.50%
Test Standard	Pharmacopoeia Sinica (CP);Enterprise Standard
Consuetudinem	Active Pharmaceutical Ingredient (API);Osteoporosis postmenopausalis

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.

commoda:

FAQ:

Applicatio:

Shanghai Ruifu Chemical Co., Ltd. est primarium fabricae et supplementi Lasofoxifene Tartrate (CAS: 190791-29-8) cum qualitate magna.
Lasofoxifene Tartrate est tertia generatio, non steroidalis, receptator modulator selectivus (SERM).Selective ERalpha ad hominem obligat cum IC50 valore 1.5 nm et iactura ossis in ovarioctomizato mures vetat.In studiis clinicis osteoporosis postmenopausalis, 0,5 mg/diei lasofoxifene sociatum est cum imminutis periculis fracturae nonvertebrarum et vertebrarum, ER-positivi cancer pectoris, morborum coronariorum, et plagae, sed auctum periculum eventuum venarum thromboembolicorum.Lasofoxifene ostensum est etiam agere ut inversum agonistam receptorem CB2 cannabinoideum, ostendens suam potentialem reponendam esse therapeuticam ad indicia in quibus CB2 signum est.